Feeds:
Posts
Comments

Posts Tagged ‘Altace’

Novartis buying up Alcon – Novartis AG has agreed to buy Nestle AG’s 77 percent stake in U.S. company Alcon for $39 billion to boost its eye care business, the Swiss drugmaker said on Monday…more

Schering: the next cut is the deepest – Faced with a crushing blow to its top selling cholesterol medicine, Schering-Plough tonight announced layoffs, plant closings and spending cuts to save $1 billion over the next two years. “No area will be exempt,” Fred Hassan, Schering-Plough’s chairman and CEO, said in a news release…more

Lots of juicy stuff from ACC (American College of Cardiology) this week:

Micardis cuts heart risk – The blood pressure drug Micardis was as effective in preventing serious heart problems in high-risk patients as certain older drugs, but with fewer side effects, international researchers said on Monday. The Boehringer Ingelheim drug Micardis, or telmisartan, is typically used in patients with heart failure, but the study found it worked as well as the ACE inhibitor ramipril, marketed in the United States as Altace by King Pharmaceuticals Inc…more

Diabetes drug Actos arresting heart disease? – The popular diabetes pill Actos prevented the build-up of fatty deposits in heart arteries in a study of patients with type 2 diabetes, U.S. researchers said on Monday. They said the Takeda Pharmaceutical Co Ltd drug Actos, known generically as pioglitazone, is the first diabetes therapy shown to reduce the progression of atherosclerosis…more, and more.

Novartis’ Lotrel very effective at cutting heart risks – Lotrel, a pill combining two blood pressure drugs in one, was so effective at preventing heart attacks and other problems in a clinical trial that the study was stopped early, and its findings may change the way hypertension is treated, U.S. researchers said on Monday…more

Merck’s experimental weight loss drug: effective, some side effects – Obese patients treated with a low dose of Merck & Co Inc’s experimental drug taranabant lost a significant amount of weight, but there were side effects, according to interim results from a pivotal trial released by the company on Monday…more

Read Full Post »

King Pharmaceuticals has suffered a setback (potential generic competitors for Altace), and will be cutting its employee base significantly.

That’s the straightforward way to say it. But when companies have to make cuts, you can be sure that the most creative use of obfuscation will come to the fore. Here’s the headline announcing this:

King Pharmaceuticals Accelerates Strategic Shift to Maximize Long-Term Growth

…and here’s a juicy quote from the CEO:

Kings existing platforms in neuroscience and hospital/acute care and aggressive business development initiatives position the Company to effectively capitalize on the positive dynamics of both marketplaces. As a result, we are now in the process of realigning our organization and optimizing the Companys cost structure, which primarily involves restructuring the size and focus of our sales force to better support the priorities of our strategic plan, explained Mr. Markison.

Always, with the job cuts, it has something to do with “optimizing cost structure” and “supporting the strategic plan.”

Full article here.

Read Full Post »